The abstract is read at the publisher; the summary is JClub's.
In Huntington’s disease gene carriers, left DTI-ALPS perivascular diffusivity indices are lower than controls at stages 1–3, with decreases up to -6.43% (Cohen’s d -0.46).
- Why it matters: Glymphatic dysfunction is implicated in Huntington’s disease, but MRI-based surrogates and how they track disease stage and clinical function across cohorts remain unclear.
- What they did: Using 2,731 MRI sessions from 880 participants in three retrospective HD cohorts, the study compared DTI-ALPS and MRI-visible EPVS across HD Integrated Staging System stages 0–3 with linear mixed-effects models and likelihood ratio tests.
- The result: EPVS burden showed stage- and region-specific changes (+49.9% to +63.7% subcortical at stages 1–3; -13.8% white matter at stage 3), and lower ALPS linked to worse motor impairment (p < 0.0001) and reduced functional capacity (p < 0.01), while both improved prediction of composite progression beyond CAG-Age Product Score and striatal volume.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.